Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of$ 0.09. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -166.67%. A quarter ago, it was expected that this medical technology company would post earnings of$ 0.09 per share when it actually produced a loss of $0.03, delivering a surprise of -133.33%.Over the last four quarters, the co ...